Phanes Therapeutics Celebrates Milestone with First Patient Dosed
Phanes Therapeutics, Inc., a clinical-stage biotech company focused on innovative drug discovery and development in oncology, has some exciting news to share. The first patient has been dosed in a clinical trial evaluating their promising drug PT886, which is being tested in combination with chemotherapy. This important milestone encompasses two cohorts: one aimed at first-line treatment for pancreatic cancers and another targeting second-line therapies for gastric and gastroesophageal junction cancers.
Discovering PT886: An Innovative Approach
Central to this clinical study is PT886, a first-in-class native IgG-like bispecific antibody (bsAb). This groundbreaking treatment specifically targets claudin 18.2 and CD47, two crucial components that could significantly enhance treatment efficacy. Notably, PT886 received orphan drug designation from the FDA for pancreatic cancer treatment last year, underscoring its potential. It has also been granted Fast Track designation for metastatic claudin 18.2-positive pancreatic adenocarcinoma, highlighting its importance in the challenging landscape of cancer therapies.
Strategic Partnerships Boost Research Initiatives
In a strategic move, Phanes has teamed up with Merck to explore the use of PT886 alongside Merck’s well-known anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). This collaboration aims to broaden the therapeutic options available for patients facing these aggressive cancer types.
Insights into the TWINPEAK Study
The ongoing multi-center Phase I/II clinical trial, known as the TWINPEAK study (NCT05482893), is carefully examining several key factors. These include safety, tolerability, pharmacokinetics, pharmacodynamics, and initial efficacy of PT886. The study focuses on patients with locally advanced or metastatic forms of gastric, gastroesophageal junction, and pancreatic cancers that have shown resistance to standard therapies. It also evaluates patients for whom these conventional treatments are considered ineffective or unsuitable.
Additional Trials Demonstrate Commitment to Research
Beyond the TWINPEAK study, Phanes is also conducting a Phase I clinical trial featuring PT886 in another dynamic healthcare area.
Phanes Therapeutics' Vision
Phanes Therapeutics, Inc. is dedicated to advancing treatments in oncology. With a strong pipeline, the company is progressing through three Phase I clinical trials. In addition to the TWINPEAK study, they are actively developing the MORNINGSTAR study, which centers on their leading monoclonal antibody program, PT199, as well as the SKYBRIDGE study involving PT217. Both PT886 and PT217 highlight the innovative strategies that Phanes Therapeutics is pursuing. They are recognized as first-in-class bispecific antibodies and have received orphan drug designation and Fast Track designation from the FDA.
Utilizing Proprietary Technology Platforms
Phanes has developed a robust pipeline through its unique technology platforms—PACbody, SPECpair, and ATACCbody. These platforms play a crucial role in creating novel biologics that address significant unmet medical needs in the field of cancer.
Frequently Asked Questions
What is PT886, and how does it work?
PT886 is a bispecific antibody that targets claudin 18.2 and CD47, offering a distinctive treatment approach for pancreatic and gastric cancers.
What designations has PT886 received?
PT886 has been awarded orphan drug designation and Fast Track designation from the FDA for its potential in treating pancreatic cancer.
How many clinical trials is Phanes currently conducting?
Phanes is currently involved in several Phase I clinical trials, including the TWINPEAK, MORNINGSTAR, and SKYBRIDGE studies.
What is the TWINPEAK study focusing on?
The TWINPEAK study aims to assess the safety, tolerability, and efficacy of PT886 in patients with advanced pancreatic and gastric cancers.
Where can I learn more about Phanes Therapeutics?
For more information about Phanes Therapeutics, you can visit their official website.
